Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Removes waste products (e.g., urea, creatinine) and excess fluid from the blood through peritoneal dialysis by diffusion and osmosis across the peritoneal membrane.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges daily; dwell time 4-6 hours; concentration selected based on ultrafiltration needs.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
None Documented
None Documented
The terminal half-life of icodextrin (as total icodextrin-derived oligosaccharides) is approximately 5-8 hours after a single dwell, reflecting clearance from the plasma compartment. Clinically, sustained levels can occur with repeated exchanges.
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Delflex-LM with Dextrose 1.5% (icodextrin) is a peritoneal dialysis solution. Icodextrin is metabolized to oligosaccharides and primarily eliminated via the peritoneal cavity during dialysis. Renal excretion is minimal (<1%). The majority of icodextrin and its metabolites are removed with the dialysate effluent.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution